EDEN PRAIRIE, Minn. & PRINCETON, N.J.--(BUSINESS WIRE)--Sept. 7, 2006--SurModics, Inc. (Nasdaq:SRDX) and X-Cell Medical, Inc. announced today that they have entered into a license agreement for the use of SurModics' Bravo(TM) Drug Delivery Polymer Matrix with X-Cell's ETHOS Drug Eluting Coronary Stent System. The ETHOS drug eluting stent incorporates the Bravo polymer matrix to deliver a second generation formulation of 17 beta-estradiol, an approved drug used in hormone replacement therapy and other indications. A principal design goal of the ETHOS stent is to enhance safety and reduce late stent thrombosis.
